On Wednesday, 18 March 2026, Pulse Biosciences (NASDAQ:PLSE) presented at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference. The company outlined its strategic focus on its novel ...
Pulse Biosciences reported a 96% rhythm control at 12 months in their EFS study using NSPFA technology. The company plans to initiate an IDE study in early Q2 2026, integrating advanced mapping ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results